---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-043699"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:20:46.020737+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BiomX Q1 net loss $7.7M; cash $21.2M; BX004 Phase 2b topline Q1 2026

## Summary
- Net loss of $7.7M for Q1 2025, compared to $17.3M in Q1 2024; R&D expenses rose to $5.3M from $4.1M.
- Cash and restricted cash $21.2M as of March 31, 2025; expects runway into Q1 2026.
- Positive Phase 2 results for BX211 in diabetic foot osteomyelitis announced March 2025; planning Phase 2/3 trial pending FDA feedback.
- BX004 Phase 2b in cystic fibrosis on track to report topline results in Q1 2026; regulatory discussions expected H2 2025.
- Shareholders approved exercise of warrants from $12M February 2025 financings in April 2025, extending operational runway.

## SEC filing metadata
- accession: 0001213900-25-043699
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025043699/0001213900-25-043699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025043699/ea0242319-8k_biomxinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-043699
- JSON: https://secwatch.observer/filing/0001213900-25-043699.json
- Plain text: https://secwatch.observer/filing/0001213900-25-043699.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.